Thermo Fisher Acquires Novasep s Viral Vector Manufacturing Business For 725 Mln Euros
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Thermo Fisher Scientific Inc. (TMO) has completed the acquisition of Henogen S.A., Groupe Novasep SAS s viral vector manufacturing business in Belgium for about 725 million euros in cash, the two companies said Friday.
Novasep s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies as well as large biopharma customers. The business will be part of Thermo Fisher s Pharma Services business within the Laboratory Products and Services Segment.
Novasep s viral vector business has two locations in Seneffe and Gosselies, Belgium. It offers more than 7,000 square meters of clinical and commercial manufacturing capacity.